High levels of merger and acquisition activity will be the big theme of year for biotech, says Morningstar's Lauren Migliore.
2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.
Health-care analyst Lauren Migliore looks at what makes a biotech firm a likely takeout candidate and reveals our top five biotech M&A picks for 2010.
M&A activity grew in 2010, and we expect deal volume to remain strong in 2011.
Home-based work makes for a good transistion for clients looking to ease into their golden years
©2012 Morningstar Advisor. All right reserved.